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On microbial invasion, the host immediately evokes innate immune responses. Recent studies have demonstrated that Toll-like
receptors (TLRs) play crucial roles in innate responses that lead not only to the clearance of pathogens but also to the eﬃcient
establishment of acquired immunity by directly detecting molecules from microbes. In terms of intracellular TLR-mediated
signaling pathways, cytoplasmic adaptor molecules containing Toll/IL-1R (TIR) domains play important roles in inﬂammatory
immune responses through the production of proinﬂammatory cytokines, nitric oxide, and type I interferon, and upregulation
of costimulatory molecules. In this paper, we will describe our current understanding of the relationship between TLRs and their
ligands derived from pathogens such as viruses, bacteria, fungi, and parasites. Moreover, we will review the historical and current
literature to describe the mechanisms behind TLR-mediated activation of innate immune responses.
1.Introduction
Innate and adaptive immunities play important roles in the
elimination of various pathogens such as viruses, bacteria,
and parasites in mammals [1–3]. The adaptive immune
system exerts highly speciﬁc responses to microbes by
producing antibodies from B cells or through the generation
of killer or helper T lymphocytes, resulting in life-long
immunological memory. This process may take weeks, or
even months, to establish suﬃcient levels of immunity.
On the other hand, the innate immune system promptly
responds to the invasion of microbes and acts as the
ﬁrst line of defense, whereby innate immune cells such as
macrophages or dendritic cells (DCs) play a central role in
theproductionofproinﬂammatorycytokinesornitricoxide.
Almost 20 years ago, Janeway proposed that pattern
recognition receptors (PRRs), which recognize pathogen-
associated molecular patterns (PAMPs) speciﬁc to each
pathogen,areexpressedoninnateimmunecellsanddiscrim-
inate self or nonself structures [4]. However, the existence of
PRRs had not been elucidated until 1996, when Hoﬀman’s
group identiﬁed “Toll” in Drosophila, a mutant defective in
antifungal defense[5]. Subsequently,a mammalian homolog
of Toll was discovered using a bioinformatics approach,
and its overexpression in mammalian cells was shown to
induce proinﬂammatory cytokines and induce expression
of costimulatory molecules to stimulate acquired immunity
[6]. This study opened new avenues for the identiﬁcation of
additional members of this family of proteins, now known
as Toll-like receptors (TLRs), in humans and mice [1–3]. To
date, more than 10 members of the TLR family have been
reported in mammals and function as PRRs, recognizing a
variety of PAMPs, such as lipopolysaccharide, lipoprotein,
nucleic acids, amongst others [1–3].
Signaling molecules that participate in Drosophila Toll
pathways, such as Dorsal, Cactus, or Pelle, had been previ-
ously identiﬁed by the isolation of the corresponding insect
mutantsinthe1980s[7].In1991,theaminoacidsequenceof
the cytoplasmic portion of interleukin-1 (IL-1) was reported
to resemble that of Drosophila Toll [8]. Since activation of
IL-1R signaling pathways activated a transcription factor,
nuclear factor kappa B (NF-κB), a mammalian homolog of
Drosophila Dorsal, the counterpart of Drosophila Toll had
been ﬁrst considered to be IL-1R at that time [8]. After
identiﬁcation of mammalian TLRs, TLRs and the IL-1R were
demonstrated to possess a highly conserved intracellular
domain,nowknownastheToll-IL-1R(TIR)domain.Ligand
recognition of TLRs causes dimerization of the cytoplasmic2 Gastroenterology Research and Practice
TIR domains, culminating in activation of downstream
intracellular signaling. Similar to Drosophila Toll signaling
andmammalianIL-1Rsignaling,TLRsignalingalsoactivates
NF-κBaswellasmitogen-activatedproteinkinases(MAPKs)
to stimulate gene expression, including proinﬂammatory
cytokines and costimulatory molecules [9]. In addition,
the mammalian TLR system establishes antiviral immune
responses predominantly through the production of type I
interferon (IFN) [10].
In this paper, we will discuss the current view of
mammalian TLR pathways, focusing on the molecular basis
of extracellular and intracellular signaling events.
2. PAMPs and TLRs
So far, there are 10 members of the human and 13 members
of the mouse TLR family that have been identiﬁed [1–
3]. TLR1-TLR10 are conserved between humans and mice,
although TLR10 is not functional in mice because of a
retroviral insertion. In addition, TLR11-13 are not present in
humans. Thus, despite some species-speciﬁc receptors, most
members are conserved in mammals.
Among the TLRs, the ligand of TLR4 was ﬁrst identiﬁed
by genetic studies. The C3H/HeJ mutant mouse strain is
hyporesponsiveness to lipopolysaccharide (LPS), a cell wall
component mainly found in Gram-negative bacteria, and
possesses a recessive autosomal mutation in the Lps locus
[11, 12]. Positional cloning of the Lps locus revealed a point
mutationintheTLR4gene.TLR4-deﬁcientmicealsoshowed
a similar hyporesponsiveness to LPS [13]. C3H/HeJ-type
TLR4 fails to activate NF-κB in response to LPS, indicating
that TLR4 is essential for the recognition of LPS in vivo.
In addition to LPS, bacterial lipoprotein moieties are
recognized by TLR1, TLR2, and TLR6. TLR1 plays an
important role in the recognition of a synthetic lipopro-
tein, N-palmitoyl-S-dipalmitoylglyceryl (Pam3) Cys-Ser-
(Lys)4 (CSK4) (Pam3CSK4), and the outer-surface lipopro-
tein of the pathogen Borrelia burgdorferi,o u t e rs u r -
face protein A (OspA) [14, 15]. TLR6 participates in
the recognition of macrophage-activating lipoprotein 2kD
(MALP-2) derived from mycoplasma [16]. Both TLR1
and TLR6 require dimerization with TLR2 to be func-
tional [16]. TLR2 is also essential for the recognition of
peptidoglycan, lipoarabinomannan, porins, Trypanosoma
cruziGlycosylphosphatidylinositol-anchoredmucin-likegly-
coproteins (tGPI-mucin), or Hemagglutinin (HA) proteins
from not only bacteria but also viruses or parasites [1].
Genomic nucleic acids from bacteria and viruses, or
their analogs, stimulate the production of proinﬂammatory
cytokines and type I IFN. Among them, immunostimulatory
bacterial DNA was ﬁrst identiﬁed in Calmette-Guerin bacilli,
which are capable of promoting antitumor activity and
inducing type I IFN (IFN-α/β) and type II IFN (IFN-γ)
in human peripheral blood leukocytes [17, 18]. Among the
TLRfamilymembers,TLR9isresponsiblefortherecognition
of unmethylated CpG DNA. TLR9 also recognizes genomic
DNA from DNA viruses such as HSV-1, HSV-2, or MCMV
[1]. As well as nucleic acids, hemozoin, a malaria-derived
insoluble crystal, is a ligand for TLR9 [19].
RNA is also a TLR ligand. TLR3 recognizes a syn-
thetic double-stranded RNA (dsRNA) analog, polyinosinic-
polycytidylic acid (poly I:C), and dsRNA derived from
Reovirus, EMCV, RSV, or West Nile virus (WNV) [1]. In
contrast to dsRNA recognition by TLR3, guanosine-rich
and uridine-rich single-stranded RNAs (ssRNAs) derived
from HIV or inﬂuenza virus are ligands for TLR7 [20,
21]. In addition, low molecular weight compounds of the
nucleoside analog imidazoquinoline, known as Imiquimod
(Aldara, R-837, S-26308), and R-848 (resiquimod, S-28463)
are synthetic TLR7 ligands [22, 23].
TLR5 and TLR11 recognize protein moieties from bac-
teria or parasites. TLR5 is essential for the recognition
of a component of bacterial ﬂagella, ﬂagellin. The highly
conserved central portion of ﬂagellin that is pivotal for
bacterial motility is bound by TLR5 [24]. TLR11 recognizes
a parasite-derived proﬁlin-like molecule that is a potent
inducer of IL-12 and known as soluble Toxoplasma antigen.
It plays an important role in parasite motility and invasion
into host cells [25, 26]. TLR11 might also recognize PAMPs
from uropathogenic bacteria, since TLR11-deﬁcient mice are
highly susceptible to the pathogen. However, the natural
ligand for TLR11 from uropathogenic bacteria has not yet
been identiﬁed [27]. Thus, TLRs recognize a number of
PAMPs from various microbes. (See Figure 1).
3. Molecular Basis of TLRs Structureand
LigandRecognition
TLRs are type I transmembrane proteins that consist of three
major domains: (1) a leucine rich extracellular domain; (2)
a transmembrane domain; (3) a cytoplasmic TIR domain.
Ligand recognition by TLRs is mediated by the extracellular
domain that harbors a leucine rich repeat (LRR) composed
of 19–25 tandem copies of the “xLxxLxLxx” motif [28].
So far, the crystal structure of TLR1, TLR2, TLR3, TLR4,
and TLR6 with or without their ligands has been resolved,
and these studies predict that the extracellular domain of
the TLRs forms a horseshoe-like structure [28]. Notably,
structural analysis and biochemical studies indicate that
all TLRs form hetero- or homodimers (e.g., TLR1/TLR2,
TLR2/TLR6, TLR3/TLR3, and TLR4/TLR4), which probably
facilitates dimerization of the cytoplasmic TIR domain to
activate intracellular signaling [28]. In the case of the
homodimersofTLR3orTLR4,directorindirectinteractions
by ionic and hydrogen bonds with their ligands are essential
for the recognition [29, 30]. On the other hand, TLR2
forms a heterodimer together with either TLR1 or TLR6
to recognize triacyl or diacyl peptides in internal protein
pockets through hydrophilic interactions [31, 32].
4. Localization of TLRs: Extracellularand
IntracellularTLRs
The TLR family can be largely divided into extracellular and
intracellularmembers.TLR1,TLR2,TLR4,TLR5,TLR6,and
TLR11 are largely localized on the cell surface to recognize






















Figure 1: Extracellular and intracellular TLRs. TLRs can be divided into extracellular and intracellular TLRs. TLR1, TLR2, TLR4, TLR5,
TLR6, and TLR11 recognize their ligands on the cell surface. On the other hand, TLR3, TLR7, TLR8, and TLR9 are intracellularly localized.
and TLR9 are intracellularly expressed in endosomal- or
lysosomal-compartments and the endoplasmic reticulum
(ER).
TLR4 is tightly bound to MD-2 on the cell surface
[33]. In addition, CD14 and LPS-binding protein (LBP) also
participate in the recognition of LPS by TLR4/MD-2. CD14
eﬃciently transfers an LBP-LPS complex to TLR4/MD-2 for
cellular activation. In addition, TLR4 is internalized into
endosomal compartments in response to LPS stimulation
[33]. For TLR2 ligand recognition, TLR1, TLR6, and a host
on non-TLR receptors, such as CD36 or Dectin-1, form
heterodimers with TLR2 and are involved in the recognition
of most TLR2 ligands or β-glucan, respectively [34, 35]. The
intracellular TLRs such as TLR3, TLR7, TLR8, and TLR9
are localized on the ER membrane in resting cells. However,
upon stimulation, they are traﬃcked to the endosomal com-
partment [36, 37]. The intracellular localization is regulated
by the ER membrane protein UNC93B, which directly inter-
acts with the intracellular TLRs [38]. Mice bearing a point
missense mutation of this gene are defective in the traﬃcking
of TLR3, TLR7, and TLR9 and fail to activate cellular
signaling [38]. Moreover, processing of the ectodomain of
TLR9 by cathepsins in the endolysosomal compartments is
required for compartment-speciﬁc activation [39, 40]. Thus,
the localization of TLRs responsible for detecting foreign
(nonself)nucleicacidsistightlyregulatedtoavoidaresponse
to self-DNA on the cell surface [41]. (See Figure 1).
5. NF-κBandMAPKActivationin
TLR-MediatedIntracellularSignaling
As discussed above, the cytoplasmic portion of TLRs shows
high similarity to that of IL-1R family members and is called
the TIR domain. Activation of TLR signaling culminates in
NF-κB and MAPKs that regulate gene expression of various
immune and inﬂammatory mediators [9]. In TLR signal-
ing, NF-κBs are sequestered by cytoplasmic IκB proteins
including nuclear inhibitor of NF-κB( I κB)α,a n dI κBβ in
unstimulated cells. Stimulation by TLR ligands mediates
degradation of these IκBs by the proteasome, a process
dependent on their phosphorylation by the IκB kinase (IKK)
complex composed of IKKα,I K K β, and NEMO (also known
as IKKγ), allowing the nuclear translocation of NF-κB[ 42].
Transcriptional activity is controlled by a variety of nuclear
proteins such as Akirin2 or the family of nuclear IκBs, IκBζ,
IκBNS, and Bcl-3 [43–45].
The activation of the IKK complex is regulated by several
MAPK kinase kinases (MAP3K) including TAK1, MEKK3,
Tpl2, and ASK1 [1]. Among them, TAK1 has been most
studied in view of its molecular role in TLR/IL-1R-mediated
IKK activation [46]. TAK1 participates in IKK activation
in a complex with TAK1-binding protein 1 (TAB1), TAB2,
and TAB3, at least in vitro [46]. However, the roles of TAB
protein family members in TLR/IL-1R-mediated signaling
remain controversial, since neither TAB1 nor TAB2-deﬁcient4 Gastroenterology Research and Practice
mice showed any abnormalities of TLR/IL-1R signaling
pathways[47–49].TheactivationoftheTAK1-TABscomplex
is regulated not by protein phosphorylation, but by lysine
63 (K63)-linked ubiquitination [50]. In contrast to K48-
linked ubiquitination that mediates proteasome-dependent
protein destruction, K63-linked ubiquitination is involved
in cellular processes such as DNA repair, in addition to
activation of the TAK1-TABs complex [51]. The formation
of K63-linked polyubiquitin chains is catalyzed by the E2
ubiquitin conjugating enzyme complex Ubc13 and Uev1A
[52]. The role of Ubc13 in TLR-mediated NF-κBa c t i v a t i o n
remains controversial, since mice lacking Ubc13 exhibit
almost normal NF-κB activation and IκB degradation in
response to TLR ligands or IL-1 [53]. The TAK1 complex
alsoregulatesactivationofMAPKs,suchasERK1/2,p38,and
JNK, to control mRNA expression or the stability of mRNA
for inﬂammatory genes by mediating phosphorylation of
AP-1 transcription family proteins [54, 55].
Upstream of the TAK1 complex, a RING ﬁnger-contai-
ning E3 ligase, TRAF6, is involved in K63-linked ubiqui-
tination-mediated signaling [1]. The activity of TRAF6 is
regulated by the family of death domain containing-IL-
1R-associated kinases (IRAKs), IRAK1, IRAK2, IRAK-M,
and IRAK-4 [56, 57]. Among them, IRAK-1, IRAK-2, and
IRAK-4 positively regulate TRAF6 activity, while IRAK-
M limits TLR/IL-1R-medaited immune responses. Genetic
studies using mice lacking IRAK-1, IRAK-2 or IRAK-4 have
demonstrated that deﬁciency of both IRAK-1 and IRAK-
2 is comparable to the lack of IRAK-4 alone, suggesting
a central role of IRAK-4 in TLR/IL-1R-mediated signaling.
Moreover, IRAK-4 interacts with an upstream adaptor
molecule, MyD88, through a homophilic interaction of the
death domain [58]. MyD88 plays a critical role in both
TLR- and IL-1R-mediated signaling pathways [59, 60]. (See
Figure 2).
6. SpeciﬁcParticipation of the TIR
Domain-ContainingAdaptor Molecules
inTLR Signaling
MyD88 is a member of the family of cytosolic TIR domain-
containing adaptor molecules. In addition to MyD88, the
family includes TIRAP (also known as Mal), TRIF (also
knownasTICAM-1),TRAM(alsoknownasTICAM-2),and
SARM. As discussed above, the cytoplasmic portion of TLRs
harbors a TIR domain, to which individual TIR domain-
containingadaptorsareselectivelyrecruitedtospeciﬁcTLRs,
generating signaling speciﬁcity for each TLR [9]. MyD88 is a
master adaptor molecule that is utilized by not only all IL-1R
family members, but also by almost all TLRs, with the excep-
tion of TLR3 [1]. TIRAP interacts with MyD88 through the
TIR domain and selectively participates in TLR2- and TLR4-
mediated MyD88-dependent signaling pathways [61, 62].
Whereas LPS, the TLR4 ligand, fails to stimulate the pro-
duction of proinﬂammatory cytokines in MyD88-deﬁcient
cells, it still activates NF-κB and MAPK and induces
gene expression of type I IFN, indicating the presence of
MyD88-independent pathways in TLR4 signaling [63, 64].
Moreover, TLR3 activates MyD88-independent signaling,
suggesting the existence of other TIR domain-containing
adaptor molecules that function in the TLR3- and TLR4-
mediated pathways [65]. TRIF plays a critical role in the
TLR3- and TLR4-mediated MyD88-independent pathways
[63, 64]. Although TRIF is bound to TLR3 through the TIR
domain, TLR4 utilizes TRAM to activate TRIF-dependent
signaling [66–68]. Thus, TLR4 utilizes MyD88 and TIRAP
for the MyD88-dependent pathway to induce mainly proin-
ﬂammatory cytokines, or TRIF and TRAM for the MyD88-
independentpathwaytoinducetypeIIFNandIFNinducible
genes(IRGs)[9].Moreover,internalizationofTLR4isshown
to be required for proper activation of the TRIF-dependent
pathway [69]. In addition, a very recent study demonstrates
atwo-stageactivationmechanismforTLR4-mediatedsignal-
ing pathways, in which assembly of a multiprotein complex
including MyD88, TRAF6, Ubc13, IKKγ,c I A P 1 / 2 ,T A K 1 ,
and TRAF3 induces K63-linked ubiquitination of cIAP1/2
that leads to degradation of TRAF3, subsequently resulting
inMyD88-signalingcomplexinducingitstranslocationfrom
membrane to the cytosol and TAK1 activation [70].
Regarding SARM, a previous biochemical report has
suggested that human SARM is required for negative regula-
tion of the TLR3-mediated MyD88-independent pathway by
inhibiting the interaction of TRIF with TLR3 [71]. However,
mice lacking SARM do not show any abnormalities in TLR3-
mediated, or other TLR-mediated, signaling, indicating the
minor role of SARM in TLR signaling pathways [72].
7. SignalingPathways for TLR-MediatedTypeI
IFN Production
TLR3/TLR4-mediated MyD88-independent (TRIF-depen-
dent) signaling induces the expression of type I IFN and
IRGs [9]. In addition, TLR7- and TLR9-mediated MyD88-
dependent pathways also lead to type I IFN production,
especially in a subtype of dendritic cells called plasmacytoid
dendritic cells (pDCs) [73]. Thus, TLR-mediated type I IFN
production is mediated by the TLR3/TLR4-mediated TRIF-
dependent or the TLR7/TLR9-mediated MyD88-dependent
pathways [1]. Expression of type I IFN is largely controlled
by IRF transcription factors, which consist of 9 members.
Among them, IRF1, IRF3, IRF7, and IRF8 are involved in
TLR-mediated type I IFN production [74].
Downstream of TRIF, two TRAF proteins, TRAF3
and TRAF6, participate in type I IFN production [75,
76]. Although deﬁciency in TRAF3 has resulted in severe
abnormalities in TRIF-mediated type I IFN production as
well as IL-10 production, it is largely normal in TRAF6-
deﬁcient cells, suggesting that TRAF3 rather than TRAF6
plays the critical role in the TLR3/TLR4-mediated TRIF-
dependent pathway [75, 76]. Signaling from TRAF3 activates
IRF3, predominantly leading to IFN-β expression [75, 76].
Phosphorylation of the C-terminal serine/threonine rich
portions of IRF3 by IKK-related kinases, TBK1 (also known
a sT 2 Ko rN A K )a n dI K K - i (also known as IKKε), is
required for this activation [77, 78]. Phosphorylated IRF3
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Figure 2: TLR-mediated MyD88-dependent or TRIF-dependent pathways. TIR domain-containing adaptors MyD88, TIRAP, TRIF, and
TRAM deﬁne TLR-mediated signaling. MyD88 and TIRAP are adaptors for the MyD88-dependent pathways, which mainly activate
proinﬂammatory cytokine production. On the other hand, TRIF and TRAM are adaptors for IRF3 activation, resulting in production of
type I IFN by TLR3- or TLR4-mediated TRIF-dependent pathways. In pDCs, TLR7/TLR9-mediated MyD88-dependent pathways induce
IRF7 activation, leading to IFNα production.
where it binds to the DNA and interacts with the nuclear
coactivator proteins p300 and CBP to positively regulate the
transcription of the IFNβ gene [79]. IKK-i and TBK1 are
boundtoTANK(alsoknownasI-TRAF),NAP1(alsoknown
as AZ2) and TBKBP1 (also known as SINTBAD) [80–82].
AlthoughthemoleculesregulatethekinaseactivitiesofTBK1
and IKK-i, much like NEMO, which critically controls IKKα
and IKKβ, their physiological roles in TLR3/TLR4-mediated
type I IFN production remain to be elucidated [1].
In vivo stimulation by TLR7 or TLR9 ligands in mice
leads to the production of high levels of IFNα, mainly from
pDCs [1]. TLR7- and TLR9-dependent IFNα production
requires MyD88, but not TRIF [83, 84]. MyD88-dependent
expression of IFNα is mediated by IRF7 [83, 84] ,ap r o t e i n
structurally related to IRF3 that plays a master role in TLR7-
andTLR9-mediatedIFNαproduction[74].LikeIRF3,which
is phosphorylated by IKK-i and TBK1 [85, 86], IRF7 is also
phosphorylated in response to TLR7 and TLR9 ligands in
pDCs, although by IRAK-1 and IKKα [83]. Moreover, PI3K,
osteopontin, TRAF3, and TRAF6 regulate IRF7 activation
[87]. In addition to IRF7, IRF1 participates in IFNβ gene
expression in conventional DCs (cDCs) [88]. IRF1 as well as
IRF7isdirectlyboundtoMyD88andactivatedinresponseto
TLR9 ligands [89]. Moreover, IRF8 also plays an important
role in IFNα and IFNβ, as well as IL-12 p40, production
by pDCs and other DCs [90]. Another IRF member, IRF5,
is indispensable for proinﬂammatory cytokine production,
rather than type I IFN, in the MyD88-dependent pathways
mediated by almost all TLRs [91]. Thus, IRFs are divergent
regulators of the production of not only type I IFN, but also
inﬂammatory cytokines. (See Figure 2).
8. Conclusions
A variety of PAMPs derived from a wide range of pathogens,
including viruses, bacteria, fungi, and parasites, are
recognized by TLRs. After ligation of the PAMPs, TLRs
initiate intracellular signaling pathways to activate immune
responses via the TIR domain. The TIR domain of the
receptor interacts with the intracellular TIR domain-
containing adaptors MyD88, TIRAP, TRIF, TRAM, and
SARM, which generate the speciﬁcity of the downstream
signaling and unique outputs of each TLR. The MyD88-
dependent pathways mainly regulate proinﬂammatory
cytokine production and IRF1- or IRF7-mediated type I
IFN production in DCs. On the other hand, TLR3- and6 Gastroenterology Research and Practice
TLR4-mediated TRIF-dependent pathways control IRF3-
mediated IFNβ production. Large bodies of the past,
current, and future literature on TLR signaling pathways can
be applied not only to liver immune cells, such as Kupﬀer
cells, but also nonimmune cells including hepatocytes and
other liver cells.
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